Lucence (@LucenceHealth) header
Lucence (@LucenceHealth) profile picture

Earlier Detection. Better Health.

Palo Alto, California
Joined August 2016
Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)Photo by Lucence (@LucenceHealth)
One biopsy may not reveal every actionable cancer alteration. Tissue and liquid biopsy offer complementary insights. In LIQUIK, liquid biopsy detected guideline-recommended biomarkers in 6 of 46 patients with negative tissue NGS. Read more: lucence.com/clinical-insight…
🤖 Made with AI
1
1
50
Thank you, @zaobaosg , for the coverage. Lucence is pleased to contribute to Singapore’s National Precision Medicine Programme, supporting genomic sequencing at population scale.
1
19
Lucence is one of two sequencing providers for Singapore’s National Precision Medicine Phase III program. Whole-genome sequencing will be performed in Singapore, with @QIAGEN and Ultima Genomics. Read more: lucence.com/news-updates/luc… #Genomics #PrecisionMedicine
3
81
What can liquid biopsy reveal that tissue testing may miss? Dr @GlopesMd shares his perspective on their complementary roles in cancer care. #LiquidBiopsy lucence.com/patient-stories/…
1
2
124
FDA advisory support for methylation-based MCED is a milestone, not the finish line. Methylation leads in evidence, but combining biomarkers may boost sensitivity while preserving specificity. What evidence will show clinical benefit? Read: lucence.com/clinical-insight…
23
Why are some cancers more common in some parts of the world? It's not just genetics. From tobacco and UV exposure to HPV, hepatitis B, betel quid, salt-preserved fish and PFAS, cancer risk reflects environment, culture and biology. Read: lucence.com/clinical-insight…
1
51
Blood isn't the only place to look for cancer. Join Dr. Guru Sonpavde and Dr. Tan Min-Han to explore the emerging role of urine tumor DNA (utDNA) in multi-cancer early detection for urologic cancers. 🗓️Nov 11, 2026 🕔5:00 PM PT 💻Live on Zoom Register now -zoom.us/webinar/register/WN_…
79
Cancer isn't written in one molecular language. DNA mutations transformed precision oncology, but they're only part of the story. Other biomarkers reveal different aspects of cancer. Read our article on how multi-omics is shaping cancer diagnostics: lucence.com/clinical-insight…
43
DNA sequencing has come a long way since 1977 From reading short DNA stretches to scanning genomes and resolving complex structures, each advance has expanded what we can see in tumors. But more sequencing doesn't always mean clearer answers. Read more: lucence.com/clinical-insight…
36
When should you start cancer screening? It depends on the cancer type and your risk factors. Our latest article covers: • Breast, cervical & lung screening • FIT vs colonoscopy • How MCED blood tests could complement routine screening Read more: lucence.com/clinical-insight…
1
49
When cancer spreads to the brain, can CSF testing provide answers blood testing may not? Dr. Daniel Chan discusses how CSF testing can identify actionable changes in brain metastases and leptomeningeal disease when blood or tissue testing isn't possible. lucence.com/patient-stories/…
78
MRI showed no brain metastases or leptomeningeal involvement. CSF cytology found no definitive malignant cells. But CSF liquid biopsy identified EGFR L858R at 42.7% VAF. Prof. Gilberto Lopes discusses the case and what followed. Full webinar: docs.google.com/forms/d/e/1F…
59
What happens when MRI and cytology are negative, but the patient continues to deteriorate? Prof. Gilberto Lopes and Dr. Min-Han Tan discuss how CSF liquid biopsy can uncover molecular insights in CNS disease that plasma may miss. Watch the webinar: docs.google.com/forms/d/e/1F…
1
137
Why don't we routinely screen for pancreatic, liver, ovarian, or bladder cancer? Cancers outside today's routine screening programs account for ~78% of cancer deaths worldwide. The challenge is balancing detection, outcomes, and harm. Read more: lucence.com/clinical-insight…
1
28
How can clinicians obtain actionable genomic insights in advanced lung cancer with CNS involvement? Join Dr. Gilberto Lopes and Dr. Tan Min-Han for a discussion on CSF liquid biopsy and CNS molecular profiling. 📅 Jul 29, 2026 | 🕗 8 PM ET 🔗 lnkd.in/efWyQVN8
1
23
ASCO 2026 asked: how early can molecular testing guide care? In stage II colon cancer, ctDNA-guided adjuvant chemotherapy reduced 3-year recurrence to 19% vs 62% with observation.¹ Read more: lucence.com/clinical-insight… ¹ Folprecht G et al. J Clin Oncol. 2026.
2
43
100 cancer subtypes ≠ 100 cancer types. Sensitivity matters. In one validated MCED study, Stage I sensitivity was 16.8% vs 90.1% in Stage IV.¹ The headline number isn't the whole story. Read more: lucence.com/clinical-insight… [1] Klein EA, et al. Ann Oncol. 2021.
1
22
Cancer prevention may begin long before cancer itself. Many risk factors— smoking, alcohol, inactivity, and air pollution—affect the same aging pathways. Our article explores why longevity medicine and cancer prevention are closely connected. Read here: lucence.com/clinical-insight…
1
20
We are honored to welcome Dr. Guru Sonpavde, Director of Phase I Clinical Research & Genitourinary Oncology and Endowed Chair of Bladder Cancer Research at AdventHealth Cancer Institute, & Professor of Medicine at University of Central Florida to Lucence Medical Advisory Board!
37
Cancer risk testing and cancer screening answer different questions: • Am I at higher risk? • Is cancer present now? Our article explains inherited cancer risk, tumor-derived signals, and how both approaches can support earlier action. Read here: lucence.com/clinical-insight…
11